AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$CTSO

Chan Phillip P. purchased $70K of CTSO

Chan Phillip P. (Chief Executive Officer) purchased 200,000 shares of Cytosorbents Corp (CTSO) at $0.35 on 2026-09-04.

Original reporting
SEC EDGAR · Chan Phillip P.
Published Sep 9, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CTSO
Neutral
medium confidence
Mentioned
$CTSO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

The purchase is a primary disclosure but small in scale, offering limited trading insight.

02

Market read

Minor insider activity with low immediate market relevance.

03

What to watch

Potential upcoming contract or product launch not disclosed.

Relevance 4/10Novelty 5/10Timing: filing today

Background

Form 4 filing reports insider transactions; CTSO is a medical device company.

Company-level read

Ticker impact

$CTSONeutralMedium confidence
Context

CEO Chan Phillip P. bought 200,000 shares for $70,000, increasing his stake to 1.94M shares.

Expected impact

Minor upward pressure, likely negligible.

Evidence & confidence

Purchase size is modest relative to float; market may view as routine insider activity.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buy could be a prelude to upcoming positive news.

Key entities

  • Company
    Cytosorbents Corp

    Issuer of the Form 4 filing.

  • Person
    Chan Phillip P.

    CEO and insider purchaser.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CTSO insider trading history →

Related articles

AUG 14
$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

fool.com6 min
JUN 2
$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

fool.com6 min